Menu
Menu
Centre Hospitalier du Pays d’Aix, a major hospital serving the Provence region in southern France, has joined the SOPHiA GENETICS global network to expand its precision oncology capabilities.
The institution is now leveraging both the SOPHiA DDM™ Myeloid Solution and Solid Tumor Targeted Applications, unlocking new layers of insight for the diagnosis and treatment of hematologic malignancies and solid tumors. These multimodal, AI-powered applications help clinicians detect actionable biomarkers more accurately, efficiently, and confidently.
With over 800 hospitals worldwide already using SOPHiA GENETICS technology, Centre Hospitalier du Pays d’Aix is now part of a growing movement to make data-driven medicine the global standard.
Explore the solutions:
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
